Dr. Luis E. Raez
@LuisRaezMD
Chief Sci Off & Med Dir Memorial Can Inst/Memorial Health Syst Past Pres. FLASCO, old account @luiseraez1 was dc, personal site
We are publishing EGFR resistant tumor data here after profiling more than 45,000 tumors, the documentation of the prevalence of resistance mutations (718,721,797 etc.) is very important however we need to increase awareness to repeat molecular profiling after TKI failure to have…
Our @FLASCO_ORG "Breaking Barriers" Conference is coming this November again! we are addressing topics to improve cancer care in Veterans, rural communities, minorities and other disadvantage populations with @Latinamd @BrainTumorDoc @EugeneManley @MikeCusnir @BlasePolite from…
Honored to speak at the @FLASCO_ORG Breaking Barriers Conference—grateful for the opportunity to join colleagues committed to advancing equity in cancer care. #Oncology #HealthEquity #CancerCare @SylvesterCancer
Our @FLASCO_ORG "Breaking Barriers" Conference is coming this November again! we are addressing topics to improve cancer care in Veterans, rural communities, minorities and other disadvantage populations with @Latinamd @BrainTumorDoc @EugeneManley @MikeCusnir @BlasePolite from…
Great discussion reviewing all the EGFR data in #lungcancer including FLAURA2 and Mariposa trials. @EGFRSummit @EGFRResisters @EgfrUk @EGFRmNSCLC @EGFRmNSCLC @Oncology_at_AZ @AstraZenecaUS @AstraZeneca
@CharuAggarwalMD, @MNagasaka,@MattGubensMD,@LuisRaezMD , and @LeXiuning discuss considerations around managing systemic progression in EGFR-mutant lung cancer. Watch more here: hubs.li/Q03yWtgs0
#FLAURA2 Catching up with the press release medical literature. Chemo+osimertinib for 1L EGFR+ NSLC now has OS advantage over osi monotherapy. ➡️Magnitude of OS benefit not reported yet , PFS 29.4 vs 19.9mo (HR 0.75) ➡️ Who gets chemo+tki vs amivantamab+TKI is the ?? ➡️ Weigh…
#lungcancer #lcsm
Registration is Open for Spanish: Targeted Therapies in Lung Cancer Patient Forum - Luis E Raez @LuisRaezMD oncodaily.com/blog/luis-raez… #OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews #TargetedTherapy
#lungcancer #lcsm @JackWestMD
Nos complace anunciarles uno de nuestros eventos más importantes del año: un foro en línea, gratuito e interactivo sobre cáncer de pulmón. Este evento está diseñado específicamente para pacientes, familiares (cuidadores) y sobrevivientes de cáncer de pulmón. Detalles del Evento:…
Great news we were waiting for the OS data for a while #lungcancer #lcsm
🔥🚨Hot Off the Press #BigNews Press Release by @AstraZeneca ⭐️#FLAURA2 trial of #Osimertinib + #Chemotherapy vs #Osimertinib in 1st line Tx for patients with #EGFR+ advanced #LungCancer (#NSCLC) shows: ✅Statistically Significant & Clinically Meaningful Improvement in…
our #lungcancer session at MECC New Orleans 2025 with @drgandara @IASLC Karen Kelly @lungoncdoc @JuliaRotow Paul Bunn Subramanian @fred_hirsch @EdgardoSantosMD Megan Daly Erminia Mazarelli #lcsm @mecmededucation
#lungcancer #LCSM
@drgandara reviews the pivotal role of liquid biopsy in making precision oncology a reality for our patients with lung cancer. #NOSCM25
#lungcancer #LCSM
Always love hearing @JuliaRotow speak! Great to spend time with her in NOLA! BOOKMARK her updated slide! 🔖
Calles et al. evaluated lurbinectedin + pembrolizumab in relapsed #SCLC pts without prior immunotherapy. The combination showed promising efficacy, especially in platinum-sensitive pts. Read more: bit.ly/3Qp3xYl #LCSM @Tony_Calles
Glad to share our article about Clinical and economic impact of the availability of innovative therapies for NSCLC patients in Latam sciencedirect.com/science/articl… Great Latin America effort led by @AndresFCardonaZ @ogarrieta @LuciaViola9 @LuisRaezMD @TheLancetOncol @LancetGH
Our @cancerGRACE Spanish Forum in cancer therapies is coming soon! pls register #lungcancer #lcsm @JackWestMD @IvyLorena_Md
¡Próximamente! 🗓️ Evento educativo virtual para pacientes con cáncer de pulmón y cuidadores. Presentaciones en vivo con expertos y sesión de preguntas y respuestas. ¡Información clave sobre tratamientos y más! Detalles de agenda y ponentes pronto. Regístrate gratis aquí:…
Our #lungcancer @cancerGRACE forum in targeted therapy in spanish #lcsm
¡Próximamente! 🗓️ Evento educativo virtual para pacientes con cáncer de pulmón y cuidadores. Presentaciones en vivo con expertos y sesión de preguntas y respuestas. ¡Información clave sobre tratamientos y más! Detalles de agenda y ponentes pronto. Regístrate gratis aquí:…
#lungcancer #sclc
Lurbinectedin Plus Pembrolizumab in Relapsed SCLC: The Phase I/II LUPER Study - Journal of Thoracic Oncology #LCSM @SclcSMASHERS jto.org/article/S1556-…